Galactosylceramide receptor (GalCer)

Galactosylceramide (GalCer) is a glycosphingolipid that serves as a critical alternative receptor for the HIV-1 envelope glycoprotein gp120, particularly on CD4-negative cells such as mucosal epithelial cells and astrocytes (Harouse et al., 1991, Science). In tissues where the canonical CD4 receptor is absent, the V3 loop of gp120 binds specifically to the galactose moiety of GalCer, facilitating viral entry or transcytosis across the epithelial barrier (Fantini et al., 1993, Journal of Virology). This interaction is a key mechanism for the initial stages of HIV-1 infection at mucosal surfaces and for the invasion of the central nervous system (Bhat et al., 1991, PNAS). Therapeutic strategies targeting this interaction include the development of GalCer analogs and specific monoclonal antibodies, such as mAb 13, designed to block the gp120 binding site (Cook et al., 1994, Journal of Virology). However, because GalCer is a fundamental component of the myelin sheath in the nervous system, systemic inhibition of this target carries a significant risk of neurotoxicity and demyelinating disorders (Coetzee et al., 1996, Cell). Consequently, drug development is often focused on localized applications, such as topical microbicides, to prevent mucosal transmission while minimizing systemic exposure.

Other names

GalactocerebrosideGal-CerGalβ1-1'CerHIV-1 gp120 alternative receptorGalactosyl ceramide

Inhibition of the binding between the HIV-1 envelope glycoprotein gp120 V3 loop and the galactose head group of the galactosylceramide receptor on CD4-negative cells, preventing viral attachment and entry.